What is Evkeeza, and what does it do?
Evkeeza (evinacumab-dgnb) is an FDA-approved treatment used to lower LDL cholesterol (LDL-C) in certain patients with severe hypercholesterolemia. It is a monoclonal antibody given by intravenous infusion and works by targeting ANGPTL3 to help reduce blood lipid levels. [1][2]
Who is Evkeeza for under FDA approval?
FDA labeling describes Evkeeza for specific groups, including patients with homozygous familial hypercholesterolemia (HoFH) and, in some cases, those with severe hypercholesterolemia who need additional LDL-C lowering beyond standard therapy. The exact approved populations and use conditions are defined in the FDA prescribing information. [1][2]
How is Evkeeza given, and how often?
Evkeeza is administered as an intravenous infusion, with the dosing frequency specified in the FDA prescribing information. [1][2]
What side effects should patients know about?
Commonly reported side effects and important warnings are listed in the FDA-approved prescribing information, including infusion-related reactions and other potential treatment effects. Patients should review the full label with their clinician. [1][2]
What is the FDA status—approval date and label details?
Evkeeza has an FDA-approved label for its indicated uses, and the full prescribing information is available through the FDA and the manufacturer’s U.S. label. For the most accurate details (indications, dosing, and safety language), use the label text. [1][2]
Where can I find the official FDA information?
You can access Evkeeza’s official information through:
- the FDA prescribing information/label [1]
- the FDA drug database entry (brand and regulatory details) [2]
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[2] https://www.fda.gov/drugs/drug-approvals-and-databases